Exchange: NASDAQ·Updated 07:15 AM EDT
KLRS logo

KLRSKalaris Therapeutics

$3.96
$0.08
(1.98%)
Pre-Market
Prev Close $4.04
Reported EarningsMay 12
Mkt Cap$87.31M
Vol186.00
News
all
press releases
Why Is Kalaris Therapeutics Stock Gaining Friday?
Kalaris Therapeutics (NASDAQ: KLRS) stock jumps 18% after releasing expanded Phase 1a data for its AMD treatment, TH103.read more...
Benzinga
More News
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers Jasper Therapeutics (NASDAQ:JSPR) stock moved upwards by 19.2% to $0.92 during Friday's regular session. The company's market cap stands at $21.6 million. Kalaris Therapeutics (NASDAQ:KLRS) sharesread more...
Benzinga
Kalaris Therapeutics Inc. (NASDAQ:KLRS) Short Interest Update
Kalaris Therapeutics Inc. (NASDAQ:KLRS - Get Free Report) saw a significant decrease in short interest in April. As of April 15th, there was short interest totaling 842,687 shares, a decrease of...
MarketBeat
Kalaris Therapeutics Inc. (NASDAQ:KLRS) Receives Consensus Recommendation of "Moderate Buy" from Analysts
Kalaris Therapeutics Inc. (NASDAQ:KLRS - Get Free Report) has earned an average rating of "Moderate Buy" from the six research firms that are covering the firm, MarketBeat reports. One investment...
MarketBeat
Kalaris Therapeutics (NASDAQ:KLRS) CAO Sells 1,915 Shares
Kalaris Therapeutics Inc. (NASDAQ:KLRS - Get Free Report) CAO Brett Hagen sold 1,915 shares of Kalaris Therapeutics stock in a transaction dated Friday, March 20th. The stock was sold at an average price of $6.72, for a total transaction of $12,868.80. The transaction was disclosed in a legal...
MarketBeat
Brett Hagen Sells 1,915 Shares of Kalaris Therapeutics (NASDAQ:KLRS) Stock
Kalaris Therapeutics Inc. (NASDAQ:KLRS - Get Free Report) CAO Brett Hagen sold 1,915 shares of the firm's stock in a transaction dated Friday, March 20th. The shares were sold at an average price of...
MarketBeat
Kalaris Therapeutics (NASDAQ:KLRS) Raised to "Hold" at Wall Street Zen
Wall Street Zen upgraded shares of Kalaris Therapeutics from a "sell" rating to a "hold" rating in a report on Sunday...
MarketBeat
Kalaris Therapeutics Inc. (NASDAQ:KLRS) Receives Average Recommendation of "Moderate Buy" from Analysts
Shares of Kalaris Therapeutics Inc. (NASDAQ:KLRS - Get Free Report) have been given a consensus rating of "Moderate Buy" by the six analysts that are presently covering the company, Marketbeat.com...
MarketBeat
Kalaris Therapeutics (NASDAQ:KLRS) Rating Lowered to Sell at Wall Street Zen
Wall Street Zen lowered shares of Kalaris Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday...
MarketBeat
Wall Street Zen Upgrades Kalaris Therapeutics (NASDAQ:KLRS) to Hold
Wall Street Zen raised Kalaris Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday...
MarketBeat
<
1
2
...
>

Advertisement|Remove ads.